Company intelligence / Profile preview

Renfu Pharmaceutical Group Co., Ltd.

Yichang, Hubei Province, Chinaen.humanwell.com.cn ↗

Ownership: Private
Employees: ~7500
Development stage: Other

Overview

The company has a broad portfolio including over 500 products under development with more than thirty new Class I drugs in development. Their clinical pipeline includes early-stage CNS drugs targeting pain indications currently in Phase I or IND stage.

Therapeutic areas: OtherDermatologyNeurology
Modalities: Small molecules (oral solid preparations, injections)Soft capsulesHigh-end pharmaceutical excipients for injection-grade and solid preparations
Industry: Biotech

Beyond the preview

Go deeper on Renfu Pharmaceutical Group Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renfu Pharmaceutical Group Co., Ltd..